5. 1), og den generelle sikkerhedsprofil var sammenlignelig med den tidligere formulering af mæslinge -, parotitis - og rubellavaccine fremstillet af Merck & Co., Inc.
In clinical trials, M-M-RVAXPRO was administered to 1965 children (see section 5.1), and the general safety profile was comparable to the previous formulation of the measles, mumps, and rubella vaccine manufactured by Merck & Co., Inc.